These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

350 related items for PubMed ID: 28496316

  • 21. Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study.
    Dahl R, Jadayel D, Alagappan VK, Chen H, Banerji D.
    Int J Chron Obstruct Pulmon Dis; 2013; 8():501-8. PubMed ID: 24159259
    [Abstract] [Full Text] [Related]

  • 22. Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study.
    Kerstjens HAM, Maspero J, Chapman KR, van Zyl-Smit RN, Hosoe M, Tanase AM, Lavecchia C, Pethe A, Shu X, D'Andrea P, IRIDIUM trial investigators.
    Lancet Respir Med; 2020 Oct; 8(10):1000-1012. PubMed ID: 32653074
    [Abstract] [Full Text] [Related]

  • 23. Role of combined indacaterol and glycopyrronium bromide (QVA149) for the treatment of COPD in Japan.
    Horita N, Kaneko T.
    Int J Chron Obstruct Pulmon Dis; 2015 Oct; 10():813-22. PubMed ID: 25960646
    [Abstract] [Full Text] [Related]

  • 24. Profile of inhaled glycopyrronium bromide as monotherapy and in fixed-dose combination with indacaterol maleate for the treatment of COPD.
    Prakash A, Babu KS, Morjaria JB.
    Int J Chron Obstruct Pulmon Dis; 2015 Oct; 10():111-23. PubMed ID: 25609944
    [Abstract] [Full Text] [Related]

  • 25. Long-term safety of glycopyrrolate: A randomized study in patients with moderate-to-severe COPD (GEM3).
    Mahler DA, Gifford AH, Satti A, Jessop N, Eckert JH, D'Andrea P, Mota F, Banerjee R.
    Respir Med; 2016 Jun; 115():39-45. PubMed ID: 27215502
    [Abstract] [Full Text] [Related]

  • 26. Indacaterol/glycopyrronium versus tiotropium or glycopyrronium in long-acting bronchodilator-naïve COPD patients: A pooled analysis.
    Muro S, Yoshisue H, Kostikas K, Olsson P, Gupta P, Wedzicha JA.
    Respirology; 2020 Apr; 25(4):393-400. PubMed ID: 31339215
    [Abstract] [Full Text] [Related]

  • 27. Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study.
    Buhl R, Gessner C, Schuermann W, Foerster K, Sieder C, Hiltl S, Korn S.
    Thorax; 2015 Apr; 70(4):311-9. PubMed ID: 25677679
    [Abstract] [Full Text] [Related]

  • 28. Role of dual bronchodilators in COPD: A review of the current evidence for indacaterol/glycopyrronium.
    Ficker JH, Rabe KF, Welte T.
    Pulm Pharmacol Ther; 2017 Aug; 45():19-33. PubMed ID: 28389258
    [Abstract] [Full Text] [Related]

  • 29. Triple therapy with salmeterol/fluticasone propionate 50/250 plus tiotropium bromide improve lung function versus individual treatments in moderate-to-severe Japanese COPD patients: a randomized controlled trial - Evaluation of Airway sGaw after treatment with tripLE.
    Saito T, Takeda A, Hashimoto K, Kobayashi A, Hayamizu T, Hagan GW.
    Int J Chron Obstruct Pulmon Dis; 2015 Aug; 10():2393-404. PubMed ID: 26604737
    [Abstract] [Full Text] [Related]

  • 30. Combination therapy with indacaterol and glycopyrronium bromide in the management of COPD: an update on the evidence for efficacy and safety.
    Ridolo E, Montagni M, Riario-Sforza GG, Baroni M, Incorvaia C.
    Ther Adv Respir Dis; 2015 Apr; 9(2):49-55. PubMed ID: 25691493
    [Abstract] [Full Text] [Related]

  • 31. Early bronchodilator action of glycopyrronium versus tiotropium in moderate-to-severe COPD patients: a cross-over blinded randomized study (Symptoms and Pulmonary function in the moRnING).
    Marin JM, Beeh KM, Clemens A, Castellani W, Schaper L, Saralaya D, Gunstone A, Casamor R, Kostikas K, Aalamian-Mattheis M.
    Int J Chron Obstruct Pulmon Dis; 2016 Apr; 11():1425-34. PubMed ID: 27418815
    [Abstract] [Full Text] [Related]

  • 32. Relieving exertional dyspnea during the 3-min constant speed shuttle test in patients with COPD with indacaterol/glycopyrronium versus tiotropium: the RED trial.
    Beaulieu J, Jensen D, O'Donnell DE, Brouillard C, Tracey L, Vincent S, Nadreau É, Bernard E, Bernard S, Maltais F.
    Ther Adv Respir Dis; 2020 Apr; 14():1753466620939507. PubMed ID: 32663102
    [No Abstract] [Full Text] [Related]

  • 33. Fixed-dose combination of indacaterol/glycopyrronium/mometasone furoate once-daily versus salmeterol/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: A randomised, Phase IIIb, non-inferiority study (ARGON).
    Gessner C, Kornmann O, Maspero J, van Zyl-Smit R, Krüll M, Salina A, Gupta P, Bostel S, Fucile S, Conde LG, Pfister P.
    Respir Med; 2020 Apr; 170():106021. PubMed ID: 32843164
    [Abstract] [Full Text] [Related]

  • 34. Response to Indacaterol/Glycopyrronium (IND/GLY) by Sex in Patients with COPD: A Pooled Analysis from the IGNITE Program.
    Tsiligianni I, Mezzi K, Fucile S, Kostikas K, Shen S, Banerji D, Fogel R.
    COPD; 2017 Aug; 14(4):375-381. PubMed ID: 28594587
    [Abstract] [Full Text] [Related]

  • 35. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial.
    Papi A, Vestbo J, Fabbri L, Corradi M, Prunier H, Cohuet G, Guasconi A, Montagna I, Vezzoli S, Petruzzelli S, Scuri M, Roche N, Singh D.
    Lancet; 2018 Mar 17; 391(10125):1076-1084. PubMed ID: 29429593
    [Abstract] [Full Text] [Related]

  • 36. Indacaterol/Glycopyrronium versus Salmeterol/Fluticasone in Patients with COPD-A Cost-Effectiveness Analysis in the Czech Republic.
    Skoupa J, Kasak V, Klimes J, Valena T.
    Value Health Reg Issues; 2018 Sep 17; 16():112-118. PubMed ID: 30539739
    [Abstract] [Full Text] [Related]

  • 37. Efficacy of tiotropium and indacaterol monotherapy and their combination on dynamic lung hyperinflation in COPD: a random open-label crossover study.
    Fujimoto K, Yamazaki H, Ura M, Kitaguchi Y.
    Int J Chron Obstruct Pulmon Dis; 2017 Sep 17; 12():3195-3201. PubMed ID: 29138547
    [Abstract] [Full Text] [Related]

  • 38. Indacaterol acetate/mometasone furoate provides sustained improvements in lung function compared with salmeterol xinafoate/fluticasone propionate in patients with moderate-to-very-severe COPD: results from a Phase II randomized, double-blind 12-week study.
    Beeh KM, Kirsten AM, Tanase AM, Richard A, Cao W, Hederer B, Beier J, Kornmann O, van Zyl-Smit RN.
    Int J Chron Obstruct Pulmon Dis; 2018 Sep 17; 13():3923-3936. PubMed ID: 30584293
    [Abstract] [Full Text] [Related]

  • 39. Treatment response to indacaterol/glycopyrronium versus salmeterol/fluticasone in exacerbating COPD patients by gender: a post-hoc analysis in the FLAME study.
    Wedzicha JA, Singh D, Tsiligianni I, Jenkins C, Fucile S, Fogel R, Shen S, Goyal P, Mezzi K, Kostikas K.
    Respir Res; 2019 Jan 08; 20(1):4. PubMed ID: 30621717
    [Abstract] [Full Text] [Related]

  • 40. Cost-effectiveness of the LABA/LAMA dual bronchodilator indacaterol/glycopyrronium in a Swedish healthcare setting.
    Price D, Keininger D, Costa-Scharplatz M, Mezzi K, Dimova M, Asukai Y, Ställberg B.
    Respir Med; 2014 Dec 08; 108(12):1786-93. PubMed ID: 25307414
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.